PMID- 15973179
OWN - NLM
STAT- MEDLINE
DCOM- 20050728
LR  - 20190713
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 79
IP  - 12
DP  - 2005 Jun 27
TI  - Reduced risk for molecular disease in patients with chronic myeloid leukemia 
      after transplantation from a KIR-mismatched donor.
PG  - 1741-7
AB  - BACKGROUND: To examine how killer-cell immunoglobulin-like receptor (KIR) ligand 
      incompatibilities effect molecular relapse (MR), we compared the occurrence of 
      bcr-abl-positive reverse-transcriptase polymerase chain reaction (RT-PCR) results 
      in 236 CML patients (pts) after human leukocyte antigen (HLA)-identical (n=158) 
      (group 1), HLA class I antigen mismatched and KIR-ligand compatible (n=49) (group 
      2), and HLA class I antigen mismatched and KIR-ligand incompatible (n=29) (group 
      3) hematopoietic stem-cell transplantation. METHODS: We performed a retrospective 
      single-center study. MR was evaluated using the real-time RT-PCR method for the 
      detection of bcr-abl transcripts. RESULTS: In the first group, 133 of 158 (84%) 
      pts were in the first chronic phase of CML, and the corresponding figures were 33 
      of 49 (67%) pts in group 2 and 19 of 29 (64%) in group 3 (P<0.05). MR occurred in 
      1 of 29 (3%) pts in group 3 compared with 62 of 158 (39%) pts in group 1 and in 
      11 of 49 (22%) pts in group 2 (P<0.001). A hematologic relapse developed in 20 of 
      158 (13%) pts in group 1, 2 of 49 (4%) pts in group 2, and in 0 of 29 (0%) pts in 
      group 3 (P<0.05). Multivariate analysis confirmed that KIR mismatches are a 
      strong independent predictor for the occurrence of MR after transplantation 
      (P<0.02). The 5-year overall survival rate did not vary greatly between the three 
      groups (67% in group 1, 52% in group 2, and 66% in group 3). CONCLUSIONS: These 
      results suggest that KIR-ligand incompatibility is an important prognostic factor 
      in the occurrence of MR after transplantation for CML.
FAU - Elmaagacli, Ahmet H
AU  - Elmaagacli AH
AD  - Department of Bone Marrow Transplantation, University Hospital of Essen, 
      Hufelandstrasse 55, 45122 Essen, Germany. ahmet.elmaagacli@uni-essen.de
FAU - Ottinger, Hellmut
AU  - Ottinger H
FAU - Koldehoff, Michael
AU  - Koldehoff M
FAU - Peceny, Rudolf
AU  - Peceny R
FAU - Steckel, Nina K
AU  - Steckel NK
FAU - Trenschel, Rudolf
AU  - Trenschel R
FAU - Biersack, Harald
AU  - Biersack H
FAU - Grosse-Wilde, Hans
AU  - Grosse-Wilde H
FAU - Beelen, Dietrich W
AU  - Beelen DW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, KIR)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Female
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Graft Rejection/*prevention & control
MH  - Graft Survival/*physiology
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Receptors, Immunologic/*genetics/*immunology
MH  - Receptors, KIR
MH  - Recurrence
MH  - Retrospective Studies
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Siblings
MH  - *Stem Cell Transplantation
MH  - Tissue Donors
MH  - Transplantation, Homologous/*immunology
EDAT- 2005/06/24 09:00
MHDA- 2005/07/29 09:00
CRDT- 2005/06/24 09:00
PHST- 2005/06/24 09:00 [pubmed]
PHST- 2005/07/29 09:00 [medline]
PHST- 2005/06/24 09:00 [entrez]
AID - 00007890-200506270-00017 [pii]
AID - 10.1097/01.tp.0000164500.16052.3c [doi]
PST - ppublish
SO  - Transplantation. 2005 Jun 27;79(12):1741-7. doi: 
      10.1097/01.tp.0000164500.16052.3c.